Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
Terminated · Phase 1 · NCT05840510
Conditions: Solid Tumor, Adult, NSCLC, Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
At a glance
- Research payments reported, 2025
- $263,509
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 6
About the trial
- Sponsor
- Mirati Therapeutics Inc. (with Aadi Bioscience, Inc.)
- Tested
- Adagrasib (drug), nab-Sirolimus (drug)
- Dates
- Started 2023-08-07; completion 2024-12-27
- Results posted
- Not yet
This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation.
From ClinicalTrials.gov, last updated 2025-04-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $263,509 in research payments for this study in 2025 (3 payments).
Products named: Krazati
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jason Luke, M.D. Hematology & Oncology · Pittsburgh, PA
- Melissa L. Johnson, MD Medical Oncology · Nashville, TN
- Marcelo V. Vailati Negrao, M.D. Medical Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $172,377
- Sarah Cannon Research Institute, Llc $62,483
- University of Pittsburgh Cancer Institute Cancer Services $28,650
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.